文献速递血脂与心血管预防冠心病

肥胖相关心血管风险与PCSK9抑制剂获益:FOURIER研究预设分析

Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER.
PubMed 文献 · J Am Coll Cardiol · 2025-12-10

FOURIER试验随机27,564例稳定动脉粥样硬化性心血管疾病患者接受evolocumab或安慰剂,中位随访2.2年。安慰剂组中BMI≥30 kg/m2者每增加5单位,主要终点风险升高11%(校正HR 1.11;95%CI 1.02-1.21)。evolocumab的相对风险降低随BMI≥30 kg/m2连续建模而递增(交互P=0.025),BMI≥35 kg/m2者相对风险降低29%(HR 0.71;95%CI 0.59-0.86),绝对风险降低5.7%。

要点

  • 肥胖的ASCVD患者主要心血管事件风险随BMI升高而增加。
  • evolocumab在BMI≥30 kg/m2患者中相对风险降低随BMI升高而更显著。
  • BMI≥35 kg/m2者绝对风险降低达5.7%,高于非肥胖者的1.4%。

核心结论

  • 肥胖合并动脉粥样硬化性心血管疾病患者主要心血管事件风险升高,evolocumab可减轻该风险。

研究设计与样本

  • FOURIER试验预设分析,随机27,564例稳定动脉粥样硬化性心血管疾病患者至evolocumab或安慰剂,中位随访2.2年。
  • 主要终点为心血管死亡、心肌梗死、卒中、不稳定型心绞痛住院或冠状动脉血运重建。

主要发现

  • 安慰剂组中BMI≥30 kg/m2者每增加5单位,主要终点风险升高11%(校正HR 1.11;95%CI 1.02-1.21)。
  • evolocumab的相对风险降低随BMI≥30 kg/m2连续建模而递增(交互P=0.025)。
  • BMI<30 kg/m2者主要终点风险降低11%(HR 0.89;95%CI 0.81-0.98),绝对风险降低1.4%。
  • BMI 30至<35 kg/m2者风险降低14%(HR 0.86;95%CI 0.75-0.98),绝对风险降低1.8%。
  • BMI≥35 kg/m2者风险降低29%(HR 0.71;95%CI 0.59-0.86),绝对风险降低5.7%。

临床怎么用

  • 对肥胖的动脉粥样硬化性心血管疾病患者,evolocumab带来的相对和绝对风险降低随BMI升高而更显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PCSK9 inhibitor evolocumab decreases the risk of major adverse cardiovascular events (MACE). The relationship between body mass index (BMI) and benefit of evolocumab remains unknown. OBJECTIVES: This study sought to investigate the association between BMI, risk of MACE, and the clinical benefit of evolocumab. METHODS: The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized 27,564 stable atherosclerotic cardiovascular disease patients to evolocumab or placebo (median follow-up 2.2 years). The primary endpoint was cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The association between BMI and cardiovascular risk was examined in the placebo arm adjusting for clinical predictors. Effect modification by treatment arm was assessed using an interaction term in the Cox model. Kaplan-Meier rates are at 3 years. RESULTS: A total of 10,942 (40%) participants had a BMI ≥30 kg/m2; 3,446 (13%) had a BMI ≥35 kg/m2. In the placebo arm, for every 5-unit-higher BMI above 30 kg/m2, there was an 11% higher risk of the primary endpoint (adjusted HR: 1.11; 95% CI: 1.02-1.21). The relative risk reduction for the primary endpoint with evolocumab was progressively greater in those with BMI ≥30 kg/m2 modeled on a continuous basis (P for interaction = 0.025). Evolocumab reduced the risk of the primary endpoint by 11% in those with a BMI <30 kg/m2 (HR: 0.89; 95% CI: 0.81-0.98), by 14% in those with BMI of 30 to <35 kg/m2 (HR: 0.86; 95% CI: 0.75-0.98), and by 29% in those with BMI ≥35 kg/m2 (HR: 0.71; 95% CI: 0.59-0.86). The corresponding absolute risk reductions were 1.4%, 1.8%, and 5.7%, respectively. CONCLUSIONS: Individuals with obesity and atherosclerotic cardiovascular disease face an elevated risk of MACE compared with those without obesity, and evolocumab helps to attenuate this risk.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kang YM, Giugliano RP, Keech AC, et al. Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER. J Am Coll Cardiol. 2025. PMID: 41369622. doi:10.1016/j.jacc.2025.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。